SCHEMBL2049433

SCHEMBL2049433

Cc1nnc(Cn2nc(Br)c3c([N+](=O)[O-])cccc32)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
POLB P06746 3/20 0.38
MEN1 O00255 1/20 0.38
AHR P35869 1/20 0.38
KMT2A Q03164 1/20 0.38
GRIN1 Q05586 3/20 0.35
GRIN2B Q13224 3/20 0.35
GSK3B P49841 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HTT P42858 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
DCTPP1 Q9H773 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PTGS2 P35354 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MITF O75030 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2045282 0.83 CSF1R (0.43) LMNAPOLBMEN1AHRKMT2A
SCHEMBL3686582 0.78 TDP1 (0.39) LMNAMEN1KMT2AALDH1A1HTT
SCHEMBL2052723 0.77 PLA2G2A (0.44) LMNAPOLBDCTPP1MAPTRAB9A
SCHEMBL2048637 0.77 CSF1R (0.45) ALDH1A1TDP1DCTPP1CSF1R
SCHEMBL15312704 0.75 CSF1R (0.38) POLBALDH1A1HTTTDP1DCTPP1
SCHEMBL2053001 0.75 DCTPP1 (0.35) POLBGRIN1GRIN2BALDH1A1HTT
SCHEMBL15312623 0.75 CSF1R (0.36) LMNAPOLBMEN1KMT2AALDH1A1
SCHEMBL2052141 0.73 CSF1R (0.40) KMT2ATDP1DCTPP1CSF1RPLA2G2A
SCHEMBL2048104 0.73 PLA2G2A (0.33) POLBALDH1A1TDP1DCTPP1HSD17B10
SCHEMBL15312544 0.73 CSF1R (0.33) POLBKMT2AALDH1A1TDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841455-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC. (US) 2014-09-23 US disclosed
EP-2516433-B1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS ARRAY BIOPHARMA INC (US) 2014-05-21 EP disclosed
EP-2516433-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS Array Biopharma, Inc. (US) 2012-10-31 EP disclosed
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors ARRAY BIOPHARMA INC. (US) 2012-10-11 US disclosed
WO-2011079076-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors AFF1, FLI1, F3 LMNA 3788/4885POLB 4520/4885MEN1 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.